SaferSkin™

SaferSkin

Details

DC Role: 
Developer
Duration: 
On going
Client: 
Open for Market

ABOUT THIS PROJECT


SaferSkin™, a powerful new test for skin sensitisation

SaferSkin™ combines three of the top methods for ITS: the Bayesian Network approach, Multiple Regression Analysis and ‘2 out of 3‘ Weight of Evidence.

For decades, animal testing was the only method for testing the potential for skin sensitisation. Today, Integrated Testing Strategies (ITS) combining in silico computer models and in vitro data offer a much better way. In short, if a similar compound is already known to cause sensitisation, the computer model can predict the probability that a new compound could as well. Today, by combining in silico and in vitro technology, scientists can weed out risks before a compound reaches consumers.

Edelweiss Connect’s new SaferSkin™ app industrializes the ITS developed at Procter & Gamble (P&G) and other large consumer product companies for skin sensitivity*. In keeping with Edelweiss Connect’s track record in collaborative scientific communities, we initially worked with P&G to make their approach, designed to respond to that company’s particular needs, relevant to all researchers. In addition, we made SaferSkin™ user-friendly, free and open-access.

New technology, new paradigm

SaferSkin™ combines three of the top methods for ITS: the Bayesian Network approach, Multiple Regression Analysis and ‘2 out of 3‘ Weight of Evidence. “SaferSkin™ is like a legal team that brings in all the evidence, so the jury can reach a verdict they are confident about,” explains Dr. Barry Hardy, CEO, Edelweiss Connect.

To pack even more power into SaferSkin™, Edelweiss Connect partnered with Eurosafe, global suppliers of biological assays, to add genomics data from the Sens-IS assay. “Sens-IS is a leading assay on the market that is genomics-based and covers many key events in skin sensitisation,” explains Dr. Christophe Chesne, CEO of Eurosafe and Biopredic International.

“The promise of this combined expertise is what motivates Edelweiss Connect,” says Dr. Hardy. “We aim to be at the front of this paradigm change, helping companies reduce, refine and replace toxicology testing on animals and make sure their products are safe. We believe these two goals are complimentary.”

*doi: 10.1007/s00204-015-1634-2

 

Latest Tweets

Edelweiss Connect (2 days ago)
RT @openrisknet: Meet us @ISMBinfo @iscb #ISMBECCB 2019 conference in #Basel, #Switzerland and learn about our tools and solutions on #comp…
Edelweiss Connect (3 weeks ago)
RT @iseult5: @nanocommons month18 meeting well underway! Updates from Cristiana on project status and @EdelweissConn Thomas Exner on our #n…
Edelweiss Connect (4 weeks ago)
RT @openrisknet: We are pleased to announce the final @OpenRiskNet workshop that will be organised in #Amsterdam, The Netherlands on 23-24…
Edelweiss Connect (4 weeks ago)
RT @MauriceAtEcvam: We're hiring! If you are specialist in organ-on-chip technologies and systems then please apply to come join our team @…
Edelweiss Connect (4 weeks ago)
RT @nanotechia: Come say hi to @EdelweissConn at #Nanopavilion2019 Stand B316 at #ChemspecEurope ! #nano #nanomaterials #nanotechnology ht…

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland
  • Phone: +41 61 633 29 78
  • Email: info@edelweissconnect.com

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA
  • Phone: +1 252 654 9003
  • Email: info@edelweissconnect.com